229 related articles for article (PubMed ID: 24351837)
1. The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo.
Zhang T; Guo P; Zhang Y; Xiong H; Yu X; Xu S; Wang X; He D; Jin X
Int J Mol Sci; 2013 Dec; 14(12):24603-18. PubMed ID: 24351837
[TBL] [Abstract][Full Text] [Related]
2. Metformin Induced AMPK Activation, G0/G1 Phase Cell Cycle Arrest and the Inhibition of Growth of Esophageal Squamous Cell Carcinomas In Vitro and In Vivo.
Cai X; Hu X; Tan X; Cheng W; Wang Q; Chen X; Guan Y; Chen C; Jing X
PLoS One; 2015; 10(7):e0133349. PubMed ID: 26196392
[TBL] [Abstract][Full Text] [Related]
3. Metformin induces G1 cell cycle arrest and inhibits cell proliferation in nasopharyngeal carcinoma cells.
Zhao L; Wen ZH; Jia CH; Li M; Luo SQ; Bai XC
Anat Rec (Hoboken); 2011 Aug; 294(8):1337-43. PubMed ID: 21717584
[TBL] [Abstract][Full Text] [Related]
4. Metformin targets a YAP1-TEAD4 complex via AMPKα to regulate CCNE1/2 in bladder cancer cells.
Wu Y; Zheng Q; Li Y; Wang G; Gao S; Zhang X; Yan X; Zhang X; Xie J; Wang Y; Sun X; Meng X; Yin B; Wang B
J Exp Clin Cancer Res; 2019 Aug; 38(1):376. PubMed ID: 31455378
[TBL] [Abstract][Full Text] [Related]
5. Anti-diabetic drug metformin inhibits cell proliferation and tumor growth in gallbladder cancer via G0/G1 cell cycle arrest.
Yamashita T; Kato K; Fujihara S; Iwama H; Morishita A; Yamana H; Kobayashi K; Kamada H; Chiyo T; Kobara H; Tsutsui K; Okano K; Suzuki Y; Masaki T
Anticancer Drugs; 2020 Mar; 31(3):231-240. PubMed ID: 31815765
[TBL] [Abstract][Full Text] [Related]
6. Metformin, an antidiabetic agent reduces growth of cutaneous squamous cell carcinoma by targeting mTOR signaling pathway.
Chaudhary SC; Kurundkar D; Elmets CA; Kopelovich L; Athar M
Photochem Photobiol; 2012; 88(5):1149-56. PubMed ID: 22540890
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma.
Luo Q; Hu D; Hu S; Yan M; Sun Z; Chen F
BMC Cancer; 2012 Nov; 12():517. PubMed ID: 23151022
[TBL] [Abstract][Full Text] [Related]
8. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
[TBL] [Abstract][Full Text] [Related]
9. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
Li C; Liu VW; Chan DW; Yao KM; Ngan HY
Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
[TBL] [Abstract][Full Text] [Related]
10. The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo.
Fujihara S; Morishita A; Ogawa K; Tadokoro T; Chiyo T; Kato K; Kobara H; Mori H; Iwama H; Masaki T
Oncotarget; 2017 Jan; 8(5):8536-8549. PubMed ID: 28052030
[TBL] [Abstract][Full Text] [Related]
11. Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP.
Zhang T; Wang X; He D; Jin X; Guo P
Anticancer Drugs; 2014 Sep; 25(8):887-97. PubMed ID: 24714080
[TBL] [Abstract][Full Text] [Related]
12. Metformin inhibits cell proliferation in SKM-1 cells via AMPK-mediated cell cycle arrest.
Zhou X; Kuang Y; Liang S; Wang L
J Pharmacol Sci; 2019 Dec; 141(4):146-152. PubMed ID: 31744691
[TBL] [Abstract][Full Text] [Related]
13. Metformin induces degradation of cyclin D1 via AMPK/GSK3β axis in ovarian cancer.
Gwak H; Kim Y; An H; Dhanasekaran DN; Song YS
Mol Carcinog; 2017 Feb; 56(2):349-358. PubMed ID: 27128966
[TBL] [Abstract][Full Text] [Related]
14. Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways.
Wang Y; Xu W; Yan Z; Zhao W; Mi J; Li J; Yan H
J Exp Clin Cancer Res; 2018 Mar; 37(1):63. PubMed ID: 29554968
[TBL] [Abstract][Full Text] [Related]
15. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Ben Sahra I; Laurent K; Loubat A; Giorgetti-Peraldi S; Colosetti P; Auberger P; Tanti JF; Le Marchand-Brustel Y; Bost F
Oncogene; 2008 Jun; 27(25):3576-86. PubMed ID: 18212742
[TBL] [Abstract][Full Text] [Related]
16. Metformin suppresses the esophageal carcinogenesis in rats treated with NMBzA through inhibiting AMPK/mTOR signaling pathway.
Fan H; Yu X; Zou Z; Zheng W; Deng X; Guo L; Jiang W; Zhan Q; Lu SH
Carcinogenesis; 2019 Jul; 40(5):669-679. PubMed ID: 30445633
[TBL] [Abstract][Full Text] [Related]
17. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner.
Rattan R; Giri S; Hartmann LC; Shridhar V
J Cell Mol Med; 2011 Jan; 15(1):166-78. PubMed ID: 19874425
[TBL] [Abstract][Full Text] [Related]
18. Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells.
Ming M; Sinnett-Smith J; Wang J; Soares HP; Young SH; Eibl G; Rozengurt E
PLoS One; 2014; 9(12):e114573. PubMed ID: 25493642
[TBL] [Abstract][Full Text] [Related]
19. NLK functions to maintain proliferation and stemness of NSCLC and is a target of metformin.
Suwei D; Liang Z; Zhimin L; Ruilei L; Yingying Z; Zhen L; Chunlei G; Zhangchao L; Yuanbo X; Jinyan Y; Gaofeng L; Xin S
J Hematol Oncol; 2015 Oct; 8():120. PubMed ID: 26503334
[TBL] [Abstract][Full Text] [Related]
20. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo.
Kato K; Gong J; Iwama H; Kitanaka A; Tani J; Miyoshi H; Nomura K; Mimura S; Kobayashi M; Aritomo Y; Kobara H; Mori H; Himoto T; Okano K; Suzuki Y; Murao K; Masaki T
Mol Cancer Ther; 2012 Mar; 11(3):549-60. PubMed ID: 22222629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
